Crossmark

Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma

Crossref DOI link: https://doi.org/10.1007/s00259-021-05336-w

Published Online: 2021-04-01

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Liang

Pang, Yizhen

Zheng, Hua

Han, Chengkun

Gu, Jianwei

Sun, Long

Wu, Hua

Wu, Sangang

Lin, Qin

Chen, Haojun https://orcid.org/0000-0002-9101-8884
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81772893, 82071961)

the key medical and health projects in Xiamen (3502Z20191104)
License Information

Text and Data Mining valid from 2021-04-01

Version of Record valid from 2021-04-01
More Information

Article History

Received: 22 January 2021

Accepted: 23 March 2021

First Online: 1 April 2021

Declarations

:

: All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.

: Informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below